Fig. 7From: Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithmComparison between the predicted time to progression (TTP) and the measured clinical TTP, including only the cases in which disease progression was determined clinically, as well as by the personalization algorithm. Points on the reference line satisfy equality between the observed and computationally derived TTPBack to article page